Search Results - "Mog, Brian"

Targeting a neoantigen derived from a common TP53 mutation by Hsiue, Emily Han-Chung, Wright, Katharine M, Douglass, Jacqueline, Hwang, Michael S, Mog, Brian J, Pearlman, Alexander H, Paul, Suman, DiNapoli, Sarah R, Konig, Maximilian F, Wang, Qing, Schaefer, Annika, Miller, Michelle S, Skora, Andrew D, Azurmendi, P Aitana, Murphy, Michael B, Liu, Qiang, Watson, Evangeline, Li, Yana, Pardoll, Drew M, Bettegowda, Chetan, Papadopoulos, Nickolas, Kinzler, Kenneth W, Vogelstein, Bert, Gabelli, Sandra B, Zhou, Shibin

“…(tumor protein p53) is the most commonly mutated cancer driver gene, but drugs that target mutant tumor suppressor genes, such as , are not yet available…”
Get full text

Detection of low-frequency DNA variants by targeted sequencing of the Watson and Crick strands by Cohen, Joshua D., Douville, Christopher, Dudley, Jonathan C., Mog, Brian J., Popoli, Maria, Ptak, Janine, Dobbyn, Lisa, Silliman, Natalie, Schaefer, Joy, Tie, Jeanne, Gibbs, Peter, Tomasetti, Cristian, Papadopoulos, Nickolas, Kinzler, Kenneth W., Vogelstein, Bert

“…Identification and quantification of low-frequency mutations remain challenging despite improvements in the baseline error rate of next-generation sequencing…”
Get full text

Targeting loss of heterozygosity for cancer-specific immunotherapy by Hwang, Michael S., Mog, Brian J., Douglass, Jacqueline, Pearlman, Alexander H., Hsiue, Emily Han-Chung, Paul, Suman, DiNapoli, Sarah R., Konig, Maximilian F., Pardoll, Drew M., Gabelli, Sandra B., Bettegowda, Chetan, Papadopoulos, Nickolas, Vogelstein, Bert, Zhou, Shibin, Kinzler, Kenneth W.

“…Developing therapeutic agents with potent antitumor activity that spare normal tissues remains a significant challenge. Clonal loss of heterozygosity (LOH) is…”
Get full text

Improving the sensitivity of in vivo CRISPR off-target detection with DISCOVER-Seq by Zou, Roger S., Liu, Yang, Gaido, Oscar E. Reyes, Konig, Maximilian F., Mog, Brian J., Shen, Leo L., Aviles-Vazquez, Franklin, Marin-Gonzalez, Alberto, Ha, Taekjip

“…Discovery of off-target CRISPR–Cas activity in patient-derived cells and animal models is crucial for genome editing applications, but currently exhibits low…”
Get full text

Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen by Wright, Katharine M., DiNapoli, Sarah R., Miller, Michelle S., Aitana Azurmendi, P., Zhao, Xiaowei, Yu, Zhiheng, Chakrabarti, Mayukh, Shi, WuXian, Douglass, Jacqueline, Hwang, Michael S., Hsiue, Emily Han-Chung, Mog, Brian J., Pearlman, Alexander H., Paul, Suman, Konig, Maximilian F., Pardoll, Drew M., Bettegowda, Chetan, Papadopoulos, Nickolas, Kinzler, Kenneth W., Vogelstein, Bert, Zhou, Shibin, Gabelli, Sandra B.

“…Specificity remains a major challenge to current therapeutic strategies for cancer. Mutation associated neoantigens (MANAs) are products of genetic…”
Get full text

Targeting public neoantigens for cancer immunotherapy by Pearlman, Alexander H, Hwang, Michael S, Konig, Maximilian F, Hsiue, Emily Han-Chung, Douglass, Jacqueline, DiNapoli, Sarah R, Mog, Brian J, Bettegowda, Chetan, Pardoll, Drew M, Gabelli, Sandra B, Papadopoulos, Nicholas, Kinzler, Kenneth W, Vogelstein, Bert, Zhou, Shibin

“…Several current immunotherapy approaches target private neoantigens derived from mutations that are unique to individual patients' tumors. However,…”
Get full text

TCR β chain-directed bispecific antibodies for the treatment of T cell cancers by Paul, Suman, Pearlman, Alexander H, Douglass, Jacqueline, Mog, Brian J, Hsiue, Emily Han-Chung, Hwang, Michael S, DiNapoli, Sarah R, Konig, Maximilian F, Brown, Patrick A, Wright, Katharine M, Sur, Surojit, Gabelli, Sandra B, Li, Yana, Ghiaur, Gabriel, Pardoll, Drew M, Papadopoulos, Nickolas, Bettegowda, Chetan, Kinzler, Kenneth W, Zhou, Shibin, Vogelstein, Bert

“…Immunotherapies such as chimeric antigen receptor (CAR) T cells and bispecific antibodies redirect healthy T cells to kill cancer cells expressing the target…”
Get more information

Bispecific antibodies targeting mutant RAS neoantigens by Douglass, Jacqueline, Hsiue, Emily Han-Chung, Mog, Brian J, Hwang, Michael S, DiNapoli, Sarah R, Pearlman, Alexander H, Miller, Michelle S, Wright, Katharine M, Azurmendi, P Aitana, Wang, Qing, Paul, Suman, Schaefer, Annika, Skora, Andrew D, Molin, Marco Dal, Konig, Maximilian F, Liu, Qiang, Watson, Evangeline, Li, Yana, Murphy, Michael B, Pardoll, Drew M, Bettegowda, Chetan, Papadopoulos, Nickolas, Gabelli, Sandra B, Kinzler, Kenneth W, Vogelstein, Bert, Zhou, Shibin

“…Mutations in the oncogenes occur in multiple cancers, and ways to target these mutations has been the subject of intense research for decades. Most of these…”
Get more information

TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers by Nichakawade, Tushar D., Ge, Jiaxin, Mog, Brian J., Lee, Bum Seok, Pearlman, Alexander H., Hwang, Michael S., DiNapoli, Sarah R., Wyhs, Nicolas, Marcou, Nikita, Glavaris, Stephanie, Konig, Maximilian F., Gabelli, Sandra B., Watson, Evangeline, Sterling, Cole, Wagner-Johnston, Nina, Rozati, Sima, Swinnen, Lode, Fuchs, Ephraim, Pardoll, Drew M., Gabrielson, Kathy, Papadopoulos, Nickolas, Bettegowda, Chetan, Kinzler, Kenneth W., Zhou, Shibin, Sur, Surojit, Vogelstein, Bert, Paul, Suman

“…Antibody and chimeric antigen receptor (CAR) T cell-mediated targeted therapies have improved survival in patients with solid and haematologic malignancies 1 –…”
Get full text

Direct Detection and Quantification of Neoantigens by Wang, Qing, Douglass, Jacqueline, Hwang, Michael S, Hsiue, Emily Han-Chung, Mog, Brian J, Zhang, Ming, Papadopoulos, Nickolas, Kinzler, Kenneth W, Zhou, Shibin, Vogelstein, Bert

“…Many immunotherapeutic approaches under development rely on T-cell recognition of cancer-derived peptides bound to human leukocyte antigen molecules on the…”
Get more information

Structural engineering of chimeric antigen receptors targeting HLA-restricted neoantigens by Hwang, Michael S., Miller, Michelle S., Thirawatananond, Puchong, Douglass, Jacqueline, Wright, Katharine M., Hsiue, Emily Han-Chung, Mog, Brian J., Aytenfisu, Tihitina Y., Murphy, Michael B., Aitana Azurmendi, P., Skora, Andrew D., Pearlman, Alexander H., Paul, Suman, DiNapoli, Sarah R., Konig, Maximilian F., Bettegowda, Chetan, Pardoll, Drew M., Papadopoulos, Nickolas, Kinzler, Kenneth W., Vogelstein, Bert, Zhou, Shibin, Gabelli, Sandra B.

“…Chimeric antigen receptor (CAR) T cells have emerged as a promising class of therapeutic agents, generating remarkable responses in the clinic for a subset of…”
Get full text

Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities by Mog, Brian J, Marcou, Nikita, DiNapoli, Sarah R, Pearlman, Alexander H, Nichakawade, Tushar D, Hwang, Michael S, Douglass, Jacqueline, Hsiue, Emily Han-Chung, Glavaris, Stephanie, Wright, Katharine M, Konig, Maximilian F, Paul, Suman, Wyhs, Nicolas, Ge, Jiaxin, Miller, Michelle S, Azurmendi, P, Watson, Evangeline, Pardoll, Drew M, Gabelli, Sandra B, Bettegowda, Chetan, Papadopoulos, Nickolas, Kinzler, Kenneth W, Vogelstein, Bert, Zhou, Shibin

“…Two types of engineered T cells have been successfully used to treat patients with cancer, one with an antigen recognition domain derived from antibodies…”
Get more information

Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers by Caushi, Justina X., Zhang, Jiajia, Ji, Zhicheng, Vaghasia, Ajay, Zhang, Boyang, Hsiue, Emily Han-Chung, Mog, Brian J., Hou, Wenpin, Justesen, Sune, Blosser, Richard, Tam, Ada, Anagnostou, Valsamo, Cottrell, Tricia R., Guo, Haidan, Chan, Hok Yee, Singh, Dipika, Thapa, Sampriti, Dykema, Arbor G., Burman, Poromendro, Choudhury, Begum, Aparicio, Luis, Cheung, Laurene S., Lanis, Mara, Belcaid, Zineb, El Asmar, Margueritta, Illei, Peter B., Wang, Rulin, Meyers, Jennifer, Schuebel, Kornel, Gupta, Anuj, Skaist, Alyza, Wheelan, Sarah, Naidoo, Jarushka, Marrone, Kristen A., Brock, Malcolm, Ha, Jinny, Bush, Errol L., Park, Bernard J., Bott, Matthew, Jones, David R., Reuss, Joshua E., Velculescu, Victor E., Chaft, Jamie E., Kinzler, Kenneth W., Zhou, Shibin, Vogelstein, Bert, Taube, Janis M., Hellmann, Matthew D., Brahmer, Julie R., Merghoub, Taha, Forde, Patrick M., Yegnasubramanian, Srinivasan, Ji, Hongkai, Pardoll, Drew M., Smith, Kellie N.

Get full text

Author Correction: Targeting public neoantigens for cancer immunotherapy by Pearlman, Alexander H, Hwang, Michael S, Konig, Maximilian F, Hsiue, Emily Han-Chung, Douglass, Jacqueline, DiNapoli, Sarah R, Mog, Brian J, Bettegowda, Chetan, Pardoll, Drew M, Gabelli, Sandra B, Papadopoulos, Nicholas, Kinzler, Kenneth W, Vogelstein, Bert, Zhou, Shibin

Get full text

629 Targeting a shared TP53 neoantigen with bispecific T cell retargeting antibody by Hsiue, Emily, Wright, Katharine, Douglass, Jacqueline, Hwang, Michael, Mog, Brian, Pearlman, Alexander, Schaefer, Annika, Aitana Azurmendi, P, Wang, Qing, Pardoll, Drew, Papadopoulos, Nickolas, Kinzler, Kenneth, Vogelstein, Bert, Gabelli, Sandra, Zhou, Shibin

“…BackgroundTP53 is the most commonly mutated cancer driver gene but drugs that target TP53 are not yet available. A peptide derived from the most common p53…”
Get full text

Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers by Caushi, Justina X., Zhang, Jiajia, Ji, Zhicheng, Vaghasia, Ajay, Zhang, Boyang, Hsiue, Emily Han-Chung, Mog, Brian J., Hou, Wenpin, Justesen, Sune, Blosser, Richard, Tam, Ada, Anagnostou, Valsamo, Cottrell, Tricia R., Guo, Haidan, Chan, Hok Yee, Singh, Dipika, Thapa, Sampriti, Dykema, Arbor G., Burman, Poromendro, Choudhury, Begum, Aparicio, Luis, Cheung, Laurene S., Lanis, Mara, Belcaid, Zineb, El Asmar, Margueritta, Illei, Peter B., Wang, Rulin, Meyers, Jennifer, Schuebel, Kornel, Gupta, Anuj, Skaist, Alyza, Wheelan, Sarah, Naidoo, Jarushka, Marrone, Kristen A., Brock, Malcolm, Ha, Jinny, Bush, Errol L., Park, Bernard J., Bott, Matthew, Jones, David R., Reuss, Joshua E., Velculescu, Victor E., Chaft, Jamie E., Kinzler, Kenneth W., Zhou, Shibin, Vogelstein, Bert, Taube, Janis M., Hellmann, Matthew D., Brahmer, Julie R., Merghoub, Taha, Forde, Patrick M., Yegnasubramanian, Srinivasan, Ji, Hongkai, Pardoll, Drew M., Smith, Kellie N.

“…PD-1 blockade unleashes CD8 T cells 1 , including those specific for mutation-associated neoantigens (MANA), but factors in the tumour microenvironment can…”
Get full text

Targeting MHC-linked wild type p53 with TCR mimic single chain diabody for cancer immunotherapy by Paul, Suman, Douglass, Jacqueline, Schaefer, Annika, Hsiue, Emily Han-Chung, Pearlman, Alexander, Mog, Brian, Hwang, Michael, Papadopoulos, Nickolas, Kinzler, Kenneth W., Vogelstein, Bert, Zhou, Shibin

“…Abstract only 2524 Background: Increased tumor suppressor protein p53 expression is observed in a wide range of human cancers. As a result there is intense…”
Get full text

Nano-Antagonist Alleviates Inflammation and Allows for MRI of Atherosclerosis by Mog, Brian, Asase, Courteney, Chaplin, Alice, Gao, Huiyun, Rajagopalan, Sanjay, Maiseyeu, Andrei

“…Specific targeting of inflammation remains a challenge in many pathologies, because of the necessary balance between host tolerance and efficacious…”
Get full text

Bispecifics and CAR T cells that target intracellular cancer driver mutations by Gabelli, Sandra, Wright, Katharine, Miller, Micheller, Hsiue, Emily Han-Chung, Hwang, Michael S., Thirawatananond, Puchong, Azurmendi, P. Aitana, Douglass, Jackie, Aytenfisu, Tihitina, Murphy, Michael, Mog, Brian J., Pearlman, Alexander H., Pardoll, Drew M.

“…Abstract only…”
Get full text

Dissecting the specificity of a TCR-mimic antibody targeting TP53 R175H mutation-derived neoantigen by Wright, Katharine, Hsiue, Emily Han-Chung, Douglass, Jacqueline, Hwang, Michael S., Mog, Brian J., Pearlman, Alexander H., Paul, Suman, DiNapoli, Sarah, Azurmendi, P. Aitana, Pardoll, Drew M., Bettegowda, Chetan, Papadopoulos, Nickolas, Kinzler, Kenneth W., Vogelstein, Bert, Gabelli, Sandra, Zhou, Shibin

“…Abstract only…”
Get full text